Zonulin, as a marker of intestinal permeability, is elevated in IgA nephropathy and IgA vasculitis with nephritis
Clinical Kidney Journal · 24.01.2023 · 16 (1) · 184-191
DOI: 10.1093/ckj/sfac214 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Kidney Journal, online erschienen am 20.09.2022. Verfasst von Qianqian Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Renal Division, Peking University First Hospital; Institute of Nephrology, Peking University; Key Laboratory of Renal Disease, Ministry of Health of …. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Beijing, National Key Research and Development Program of China.
Abstract (Originalsprache)
Background
Immunoglobulin A nephropathy (IgAN) and IgA vasculitis with nephritis (IgAV-N) are considered related diseases and share some similar clinicopathologic phenotypes. Elevated circulating galactose-deficient IgA1 (Gd-IgA1)-containing immune complexes and mucosal immunity were associated with the pathogenesis of IgAN and IgAV-N. Recently, studies have identified that the zonulin level, as a modulator of intestinal permeability, is significantly elevated in several inflammatory and autoimmune-related diseases. However, whether zonulin also plays a role in IgAN and IgAV-N is not clear.
Methods
A total of 73 IgAV-N patients, 68 IgAN patients and 54 healthy controls were assessed for circulating zonulin and Gd-IgA1 levels by enzyme-linked immunosorbent assay. The diagnostic efficiency of the combination of zonulin with Gd-IgA1 was evaluated by the area under the receiver operating characteristic curve (AUC) and integrated discrimination improvement (IDI) analysis.
Results
Compared with healthy controls, we found that both IgAV-N and IgAN patients had elevated zonulin and Gd-IgA1 levels (P < .001). Additionally, patients with IgAV-N presented with even higher circulating zonulin levels than patients with IgAN (P = .020). The addition of zonulin to Gd-IgA1 showed better predictive performance than Gd-IgA1 alone in the diagnosis of both IgAN and IgAV-N, as illustrated by a significantly increased AUC (IgAN: 0.805 versus 0.708, P = .0021; IgAV-N: 0.886 versus 0.673, P < .001) and significant IDI (IgAN: IDI 0.136, P < .001; IgAV-N: IDI 0.281, P < .001).
Conclusion
Elevated circulating zonulin levels were detected in both patients with IgAV-N and those with IgAN. Combined detection of circulating zonulin and Gd-IgA1 is recommended as a noninvasive diagnostic biomarker for IgAV-N and IgAN.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Renal Division, Peking University First Hospital; Institute of Nephrology, Peking University; Key Laboratory of Renal Disease, Ministry of Health of China; Key Laboratory of CKD Prevention and Treatment, Ministry of Edu…
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Beijing
- National Key Research and Development Program of China
- National High Level Hospital Clinical Research Funding
- CAMS Innovation Fund for Medical Sciences
Zitieren
APA
Li, Q., Yuan, X., Shi, S., Liu, L., Lv, J., Zhu, L., & Zhang, H. (2023). Zonulin, as a marker of intestinal permeability, is elevated in IgA nephropathy and IgA vasculitis with nephritis. Clinical Kidney Journal, 16(1), 184-191. https://doi.org/10.1093/ckj/sfac214
Vancouver
Li Q, Yuan X, Shi S, Liu L, Lv J, Zhu L, et al. Zonulin, as a marker of intestinal permeability, is elevated in IgA nephropathy and IgA vasculitis with nephritis. Clinical Kidney Journal. 2023;16(1):184-191. doi:10.1093/ckj/sfac214
BibTeX
@article{Li2023,
author = {Li, Qianqian and Yuan, Xiaohan and Shi, Sufang and Liu, Lijun and Lv, Jicheng and Zhu, Li and Zhang, Hong},
title = {Zonulin, as a marker of intestinal permeability, is elevated in IgA nephropathy and IgA vasculitis with nephritis},
journal = {Clinical Kidney Journal},
year = {2023},
volume = {16},
number = {1},
pages = {184--191},
doi = {10.1093/ckj/sfac214}
}
EUVIMED